Epigenetic co-repressors of the gamma-globin gene and methods of using same
This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.
1. A method of screening for compounds that stimulate expression of a gamma-globin gene, wherein said method comprises the steps of:
contacting a recombinant non-erythroid host cell with a test compound, wherein the recombinant non-erythroid host cell comprises an exogenous nucleic acid sequence encoding a DNA methyltransferase I (DNMT1) polypeptide and a nucleic acid sequence encoding a detectable polypeptide operably linked to a human gamma-globin gene promoter; and
measuring the amount of the detectable polypeptide in the presence and absence of the test compound, wherein an increase in the amount of the detectable polypeptide in the presence of the test compound compared to the amount of the detectable polypeptide in the absence of the test compound identifies a selected test compound as a compound that stimulates expression of the gamma-globin gene.
2. A method of screening for compounds that stimulate expression of a gamma-globin gene, wherein said method comprises the steps of:
contacting a recombinant non-erythroid host cell with a test compound, wherein the recombinant non-erythroid host cell comprises an exogenous nucleic acid sequence encoding the lysine-specific histone demethylase (LSD)-1 polypeptide and a nucleic acid sequence encoding a detectable polypeptide operably linked to a human gamma-globin gene promoter; and
measuring the amount of the detectable polypeptide in the presence and absence of the test compound, wherein an increase in the amount of the detectable polypeptide in the presence of the test compound compared to the amount of the detectable polypeptide in the absence of the test compound identifies a selected test compound as a compound that stimulates expression of gamma-globin gene.
3. A method of screening for compounds that de-repress a human gamma-globin gene, wherein said method comprises the steps of:
contacting a recombinant non-erythroid host cell with a test compound, wherein the recombinant non-erythroid host cell comprises an exogenous nucleic acid sequence encoding a TR2 polypeptide, an exogenous nucleic acid sequence encoding a TR4 polypeptide, an exogenous nucleic acid sequence encoding a DNMT1 polypeptide or a LSD-1 polypeptide or both, and a nucleic acid sequence encoding a detectable polypeptide operably linked to a human gamma-globin gene promoter, and optionally, one or more nucleic acids encoding a nucleosome remodeling and deacetylase (NuRD) complex, a CoREST complex, an HDAC3 polypeptide, and a transcriptional intermediary factor (TIF)-1 beta polypeptide; and
measuring an amount of the detectable polypeptide in the presence and absence of the test compound, wherein an increase in the amount of the detectable polypeptide in the presence of the test compound compared to the amount of the detectable polypeptide in the absence of the test compound identifies a selected test compound as a compound that de-represses the human gamma-globin gene.
4. The method of claim 1 , 2 or 3 , wherein the compounds are selected from the group consisting of small molecules, polypeptides, synthetic compounds, naturally-occurring compounds, antibodies, antigen-binding fragment, and antigens.
5. The method of claim 1 , 2 or 3 , wherein at least two of the nucleic acid sequences in claim 1 , 2 or 3 is heterologous to the recombinant cell.
6. The method of claim 1 , 2 or 3 , wherein the detectable polypeptide is selected from the group consisting of luciferase, beta-glucuronidase (GUS), beta-galactosidase, and chloramphenicol acetyltransferase (CAT).
7. A method of treating a beta-globin disorder in an individual in need of such treatment, comprising the steps of:
administering an effective amount of a compound that inhibits LSD-1 to an individual suffering from a beta-globin disorder, wherein the effective amount of the compound that inhibits LSD-1 is an amount that de-represses the human gamma-globin gene; and
detecting expression of the gamma-globin gene in the individual, thereby treating the beta-globin disorder.
8. The method of claim 7 , wherein the compound that inhibits LSD-1 is selected from the group consisting of a tranylcypromine, a polyamine, and a 2-PCPA.
9. The method of claim 7 , wherein the beta-globin disorder is selected from the group consisting of sickle cell disease and beta-thalassemia.
10. A method of treating a beta-globin disorder in an individual in need of such treatment, comprising the steps of:
identifying an individual having a beta-globin disorder; and
administering an effective amount of a compound that inhibits LSD-1 to an individual suffering from a beta-globin disorder, wherein the effective amount of the compound that inhibits LSD-1 is an amount that de-represses the human gamma-globin gene, thereby treating the beta-globin disorder.
11. The method of claim 10 , wherein the compound that inhibits LSD-1 is selected from the group consisting of a tranylcypromine, a polyamine, and a 2-PCPA.
12. The method of claim 10 , wherein the beta-globin disorder is selected from the group consisting of sickle cell disease and beta-thalassemia.